TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29656304

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant (GCI) applied in the pelvic cavity after total mesorectal excision (TME)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group without GCI
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant (GCI)
Number of subjects: 176
Study: 27355231

Group type: EXPERIMENTAL
Intervention: Sublingual methylcobalamin (1mg/day for 3 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intramuscular hydroxocobalamin injection (1mg)
Number of subjects: 34
Study: 24989822

Group type: EXPERIMENTAL
Intervention: Pamphlet-based physical activity intervention
Number of subjects: 30
Study: 22846707

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Symptom diary control
Number of subjects: 42
Study: 19776646

Group type: EXPERIMENTAL
Intervention: Repeat beta-methasone (12 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Repeat beta-methasone
Number of subjects: 22
Study: 18272913

Group type: EXPERIMENTAL
Intervention: First-line carboplatin/taxane chemotherapy, with carboplatin dose determined by measured glomerular filtration rate (GFR) and taxane dose not capped.
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: First-line carboplatin/taxane chemotherapy
Number of subjects: 1067
Study: 15720089

Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 17
Study: 15362516

Group type: EXPERIMENTAL
Intervention: 1000 mg TU (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1000 mg TU plus 150 mg DMPA (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1000 mg TU plus 300 mg DMPA (Group C)
Number of subjects: 30
Study: 11323327

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both regimens (Remifentanil and Fentanyl)
Number of subjects: 0
Study: 9152490

Group type: EXPERIMENTAL
Intervention: Heparinized human albumin (NSA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heparinized saline (NS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (NS and NSA)
Number of subjects: 40
Study: 7954484

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 49
Study: 3502238

Group type: EXPERIMENTAL
Intervention: TFX and Levamisol
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Complex herb preparation PADMA
Number of subjects: 117

Group type: COMPARATOR
Intervention: Climatotherapy in Czerniawa Sanatorium (Control)
Number of subjects: 117
Study: 29777264

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg once daily
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study: 27354683

Group type: EXPERIMENTAL
Intervention: IFN α Kinoid (IFN‐K)
Number of subjects: 6
Study: 24004458

Group type: EXPERIMENTAL
Intervention: Minimalist footwear (MFW)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional running shoes (CRS)
Number of subjects: 10
Study: 22541842

Group type: EXPERIMENTAL
Intervention: Newly developed mirtazapine tablet formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established branded mirtazapine tablet formulation
Number of subjects: 0
Study: 20859551

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan + hydrochlorothiazide (Aml/Val+HCTZ)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Amlodipine + hydrochlorothiazide (Aml+HCTZ)
Number of subjects: 344
Study: 18665688

Group type: EXPERIMENTAL
Intervention: Brief group cognitive-behavioral (CB) intervention
Number of subjects: 341

Group type: COMPARATOR
Intervention: Supportive-expressive intervention
Number of subjects: 341

Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 341

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 341
Study: 17409842

Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin-paclitaxel combination chemotherapy (1000 mg/m gemcitabine on days 1 and 8, carboplatin AUC 5 on day 1, 175 mg/m paclitaxel on day 1 for three cycles)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gemcitabine-carboplatin-paclitaxel combination chemotherapy
Number of subjects: 44
Study: 12854835

Group type: EXPERIMENTAL
Intervention: Prevalent vertebral fractures
Number of subjects: 677

Group type: COMPARATOR
Intervention: No prevalent vertebral fractures
Number of subjects: 677
Study: 10795771

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg bolus intravenous, followed after 2 h by a continuous infusion of 25 microg/hr for 20 hr)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8642191

Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg, increased to 2 mg after 15 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg, increased to 20 mg after 15 days
Number of subjects: 73
Study: 1557569

Group type: EXPERIMENTAL
Intervention: Bayesian subset analysis
Number of subjects: 0
Study: 3905203

Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 80

Group type: COMPARATOR
Intervention: Niopam 300
Number of subjects: 80
Study: 29933147

Group type: EXPERIMENTAL
Intervention: Integrated care (IC) intervention consisting of nurse-led risk factor management, group-based counseling, individual problem-solving therapy, and antidepressant medications as needed.
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Integrated care (IC) intervention
Number of subjects: 4000
Study: 26647376

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 181

Group type: COMPARATOR
Intervention: VUR alone
Number of subjects: 181

Group type: COMPARATOR
Intervention: BBD alone
Number of subjects: 181

Group type: COMPARATOR
Intervention: Neither BBD nor VUR
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: BBD
Number of subjects: 181
Study: 24866574

Group type: EXPERIMENTAL
Intervention: 6-month pretreatment with octreotide LAR
Number of subjects: 62

Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 62
Study: 23078431

Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg/day) for 8 weeks
Number of subjects: 185
Study: 20557811

Group type: EXPERIMENTAL
Intervention: rhPDGF (0.9 to 2.7 mg)
Number of subjects: 60
Study: 18557665

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 31
Study: 15863376

Group type: COMPARATOR
Intervention: Standard treatment (75 mg/m² cyclophosphamide orally on days 1-14, 60 mg/m² epirubicin and 500 mg/m² fluorouracil intravenously on days 1 and 8 for six cycles every 28 days for 6 months)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Dose-intensive treatment (830 mg/m² cyclophosphamide and 120 mg/m² epirubicin intravenously on day 1, and 5 microg/kg filgrastim subcutaneously on days 2-13 for six cycles every 14 days for 3 months)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Dose-intensive treatment
Number of subjects: 224
Study: 12027927

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 294

Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 294
Study: 10342414

Group type: EXPERIMENTAL
Intervention: Topical lidocaine patch
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle (placebo) patch
Number of subjects: 32
Study: 7732344

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (other FD patients)
Number of subjects: 100
Study: 2149674

Group type: EXPERIMENTAL
Intervention: 5, 10, 20, or 40 mg of fosinopril orally once daily for four weeks
Number of subjects: 418

Group type: COMPARATOR
Intervention: Matched placebo orally once daily for four weeks
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide added during the final four weeks
Number of subjects: 418
Study: 7025264

Group type: EXPERIMENTAL
Intervention: Tri-potassium di-citrato bismuthate (TDB) chewing tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine tablets
Number of subjects: 60
Study: 31353997

Group type: EXPERIMENTAL
Intervention: Ibuprofen gel with 3% w/w levomenthol
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Diclofenac gel (1.16%)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ibuprofen gel (5% w/w)
Number of subjects: 182
Study: 28756902

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg on day 1)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 452
Study: 26547145

Group type: EXPERIMENTAL
Intervention: Girls First Resilience Curriculum (RC)
Number of subjects: 2308

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2308
Study: 24015626

Group type: EXPERIMENTAL
Intervention: H-UPPP surgery with removal of partial pharyngeal muscle (Experimental group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: H-UPPP surgery without removal of partial pharyngeal muscle (Control group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Comparison of L1, L2, L3 measurements between groups
Number of subjects: 82
Study: 22027686

Group type: EXPERIMENTAL
Intervention: Low-fat diet with 5 grams of fish oil daily (omega-6:omega-3 ratio of 2:1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control Western diet (omega-6:omega-3 ratio of 15:1)
Number of subjects: 55
Study: 19378232

Group type: EXPERIMENTAL
Intervention: Rapid intravenous volume expansion (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No expansion (group B)
Number of subjects: 20
Study: 17530112

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Nicotine patch and bupropion
Number of subjects: 131
Study: 15387158

Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief outpatient commitment or none
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved treatment adherence
Number of subjects: 0
Study: 11488180

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11148914

Group type: EXPERIMENTAL
Intervention: Patients with alcohol dependence syndrome (21 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group of healthy persons (24 persons)
Number of subjects: 21
Study: 9247986

Group type: EXPERIMENTAL
Intervention: 1.6 mg melatonin
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 1520054

Group type: EXPERIMENTAL
Intervention: Quinine sulfate (200 mg at supper and 300 mg at bedtime)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 U at bedtime)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6241767

Group type: EXPERIMENTAL
Intervention: 10 micrograms HBV vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 micrograms HBV vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 micrograms HBV vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 100
Study: 31028216

Group type: EXPERIMENTAL
Intervention: Ahmed valve
Number of subjects: 552

Group type: COMPARATOR
Intervention: Baerveldt implant
Number of subjects: 552
Study: 29526236

Group type: EXPERIMENTAL
Intervention: Amla (Phyllanthus emblica L.) 500 mg tablets, two tablets twice a day for 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo tablets similar to Amla prescription
Number of subjects: 68
Study: 26922847

Group type: EXPERIMENTAL
Intervention: Conventional TENS therapy for 20 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham TENS therapy
Number of subjects: 30
Study: 25034632

Group type: EXPERIMENTAL
Intervention: Prism glasses
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Visual search training
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study: 23107591

Group type: EXPERIMENTAL
Intervention: Fluvirin inactivated vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Afluria inactivated vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fluarix inactivated vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Live influenza vaccine (Flumist)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inactivated vaccines (general)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Live vaccine
Number of subjects: 100
Study: 20552817

Group type: EXPERIMENTAL
Intervention: Complex Decongestive Therapy (CDT) alone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Modified CDT (MCDT) combined with Intermittent Pneumatic Compression (IPC)
Number of subjects: 112
Study: 18568788

Group type: COMPARATOR
Intervention: Estrogen-progestin treatment (EPT) in premenopausal women
Number of subjects: 35

Group type: COMPARATOR
Intervention: Estrogen-progestin treatment (EPT) in postmenopausal women
Number of subjects: 35
Study: 16075681

Group type: EXPERIMENTAL
Intervention: Thyramin bioregulator
Number of subjects: 0
Study: 12095178

Group type: EXPERIMENTAL
Intervention: Zafirlukast (14-day course)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 13
Study: 10636373

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 0
Study: 8565024

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg twice daily
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nabumetone 1500 mg once daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 2035374

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg daily if serum cholesterol < 300 mg/dl; 40 mg daily if serum cholesterol ≥ 300 mg/dl)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conventional therapy alone (control group)
Number of subjects: 157
Study: 30670666

Group type: EXPERIMENTAL
Intervention: Flow indicator covered
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flow indicator covered after standard exposure (Group B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flow indicator covered before standard exposure (Group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 42
Study: 28544580

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled cohort (MMF + CYC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CYC in SLS I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in SLS I
Number of subjects: 0
Study: 27041740

Group type: EXPERIMENTAL
Intervention: Parent-guided conversations focusing on children's feelings
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Parent-guided conversations focusing on the content of the video
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Less stress (self‐reported happiness and observed negative affect) before and after the stressor
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Younger age and parent insecure attachment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Manipulation of parents' emotion orientation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Individual differences in the talk
Number of subjects: 43
Study: 25338187

Group type: EXPERIMENTAL
Intervention: CBT/exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 80
Study: 21945174

Group type: EXPERIMENTAL
Intervention: dietary intervention with probiotics
Number of subjects: 256

Group type: COMPARATOR
Intervention: control group (placebo)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: gestational diabetes mellitus
Number of subjects: 256
Study: 20307273

Group type: EXPERIMENTAL
Intervention: Participation in the trial
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Conditional altruism
Number of subjects: 13
Study: 16481564

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) delivered to the superior temporal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study: 15957137

Group type: EXPERIMENTAL
Intervention: High-energy and high-protein supplementation (an extra 475 kcal and 16.6 g of protein daily; group A; n = 12)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Standard-energy, high-protein supplementation (an extra 67.2 kcal and 16.8 g of protein daily; group B; n = 27)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched well-nourished patients; group C; n = 16)
Number of subjects: 39
Study: 12358906

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 1.0 microg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2.25 microg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 4.5 microg/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 10444320

Group type: COMPARATOR
Intervention: Written instructions only
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined oral and written instructions
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Acceptability of the test
Number of subjects: 160
Study: 7778152

Group type: EXPERIMENTAL
Intervention: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and 500 mg at 30 h (group A)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and placebo at 30 h (group B)
Number of subjects: 159
Study: 2176795

Group type: EXPERIMENTAL
Intervention: Diltiazem (10 micrograms/kg/min for 90 to 120 minutes following skin incision)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 23
Study: 7425395

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 18
Study: 30853262

Group type: EXPERIMENTAL
Intervention: Test meal (16% total sugar, 26% saturated fat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control meal (8% total sugar, 5% saturated fat)
Number of subjects: 16
Study: 30710858

Group type: EXPERIMENTAL
Intervention: Neural gliding
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neural tensioning
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neural gliding and tensioning
Number of subjects: 48
Study: 28942807

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day for 6- to 9-year-olds; 850 mg twice a day for 10- to 17-year-olds)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25476069

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3 mg, six 2-monthly oral doses over 1 year)
Number of subjects: 240
Study: 24382824

Group type: EXPERIMENTAL
Intervention: 3-month DAPT arm
Number of subjects: 2420

Group type: COMPARATOR
Intervention: 12-month DAPT arm
Number of subjects: 2420
Study: 22992312

Group type: EXPERIMENTAL
Intervention: A multifaceted intervention to increase the use of antenatal corticosteroids, including training health providers and distributing kits with dexamethasone.
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Standard delivery of care in selected populations.
Number of subjects: 60000
Study: 19297212

Group type: EXPERIMENTAL
Intervention: Aspirin (75mg) and cilostazol (100mg twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Aspirin (75mg) and placebo
Number of subjects: 19
Study: 16176310

Group type: EXPERIMENTAL
Intervention: Computer preparation package
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Cartoon preparation package
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 14559421

Group type: EXPERIMENTAL
Intervention: Participative standard and performance feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Production standards with feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (earlier laboratory study with college students)
Number of subjects: 0
Study: 10368452

Group type: EXPERIMENTAL
Intervention: Technetium-99m hexamethyl propylenamine oxime (Tc-99m HMPAO) lung clearance study
Number of subjects: 36
Study: 8912110

Group type: EXPERIMENTAL
Intervention: Therapeutic community principles applied in acute care psychiatric treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control units (not specified)
Number of subjects: 0
Study: 2069736

Group type: EXPERIMENTAL
Intervention: 1 g/kg ethanol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 7201645

Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25 mg twice daily) for 3 cycles
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 1 cycle
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31453767

Group type: EXPERIMENTAL
Intervention: Radioembolization (RE) in Group A
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Radioembolization (RE) in Group B
Number of subjects: 48
Study: 29200372

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 100
Study: 26296069

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 12
Study: 24437213

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Double AHT (ramipril or losartan + HCT or amlodipine)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Triple therapy (ramipril or losartan + amlodipine + HCT)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 347